Aura BioSciences banks $4.5M from private backers

Cambridge, MA-based Aura BioSciences says it has rounded up $4.5 million from unnamed investors to back its work on an innovative nanotech delivery system for cancer drugs. As Xconomy notes, Aura is working with nanoparticles engineered to resemble a virus. "We retain the intelligence of the virus particles so they only target tumors," CEO Elizabeth de los Pinos, an Eli Lilly veteran, tells the tech news service. "Because they are empty shells, they never replicate. We further modified them so the immune system won't trap them." Story

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.